NOVEL STRA6 POLYPEPTIDES

• US 20080299547A1
• Filed: 07/18/2006
• Published: 12/04/2008
• Est. Priority Date: 01/13/2000
• Status: Active Grant

• Current Assignee: Genentech, Inc. (Roche Holding AG)
• Original Assignee: Genentech, Inc. (Roche Holding AG)
• Inventors: Smith, Victoria, Wood, William I., Pennica, Diane
• Granted Patent: US 7,939,650 B2
• Time in Patent Office: Days
• US Class Current: 435/6.17
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 38/1709 from mammals
• CPC Class Codes: A61P 31/00 Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: C07K 14/47 from mammals
• CPC Class Codes: C07K 2317/569 Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
• CPC Class Codes: C07K 2319/00 Fusion polypeptide
• CPC Class Codes: C12N 15/1034 Isolating an individual clone by screening libraries
• CPC Class Codes: C12N 15/85 for animal cells
• CPC Class Codes: G01N 33/574 for cancer

Abstract

The present invention is directed to novel polypeptides having sequence similarity to Stra6, a murine retinoic acid responsive protein, and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.

Claims

1-61. -61. (canceled)

62. A method of diagnosing tumor in a mammal, said method comprising detecting expression of Stra6 polypeptide in a test sample of tissue or cells obtained from the mammal, and (b) comparing expression of Stra6 polypeptide in the test sample to expression of Stra6 polypeptide in a control sample of normal tissue or cells of the same type as the test sample, wherein a higher expression of Stra6 polypeptide in the test sample as compared to the control sample is indicative of the presence of a tumor in the mammal.

63. A method of diagnosing tumor in a mammal, said method comprising (a) contacting an anti-Stra6 antibody with a test sample of tissue or cells obtained from the mammal, and (b) detecting formation of a complex between said antibody and a Stra6 polypeptide in the test sample, wherein the formation of a complex is indicative of the presence of tumor in said mammal.

64. The method of claim 63 wherein said antibody is detectably labeled.

65. The method of claim 63 wherein said test sample of tissue or cells is obtained from an individual suspected of having neoplastic cell growth or proliferation.

96. The method of claim 63, wherein detecting expression of Stra6 polypeptide comprises detecting expression of a polynucleotide encoding Stra6 polypeptide.

97. The method of claim 63, wherein the anti-Stra6 antibody comprises an antibody fragment, single chain antibody, diabody, or linear antibody.

98. The method of claim 97, wherein the antibody fragment comprises a Fab, Fab′

F(ab′

)₂, or Fv fragment.

99. The method of claim 63, wherein the anti-Stra6 antibody binds to a polypeptide comprising at least 99% sequence identity to:

(a) the sequence of amino acid residues 1 to 667 of FIG. 2 (SEQ ID NO;

2);

(b) the sequence of amino acids 1 to 658 of FIG. 7 (SEQ ID NO;

5);

(c) the full length polypeptide encoded by the human cDNA deposited with the ATCC on Jan. 11, 2000 under ATCC Deposit No. PTA-1181 (DNA148380-2827);

or

(d) the full length polypeptide encoded by the human cDNA insert of the vector deposited with the ATCC on Feb. 23, 2000 as ATCC Deposit No. PTA-1405 (DNA 148389-2827-1).

66. A cancer diagnostic kit comprising an anti-Stra6 antibody and a carrier in suitable packaging.

67. The kit of claim 66 which further comprises instructions for using said antibody to detect the presence of a Stra6 polypeptide in a sample suspected of containing the same.

68-82. -82. (canceled)

83. A method of identifying a compound that inhibits a biological or immunological activity of a Stra6 polypeptide, said method comprising contacting a candidate compound with said polypeptide under conditions and for a time sufficient to allow the two components to interact and determining whether a biological or immunological activity of said polypeptide is inhibited.

84. The method of claim 83, wherein said candidate compound or said Stra6 polypeptide is immobilized on a solid support.

85. The method of claim 84, wherein the non-immobilized component is detectably labeled.

88. The method of claim 83, wherein said candidate compound is an antibody or antibody fragment.

86. A method for identifying a compound that inhibits an activity of a Stra6 polypeptide, said method comprising the steps of (a) contacting cells expressing Stra6 polypeptide with a candidate compound, and (b) determining if the test compound inhibits a cellular response induced by expression of Stra6 polypeptide, wherein inhibition of said cellular response is indicative of said candidate compound being an effective inhibitor of Sta6 polypeptide.

87. A method for identifying a compound that inhibits expression of a Stra6 polypeptide in cells that express said polypeptide, wherein said method comprises contacting said cells with a candidate compound, and determining whether expression of said Stra6 polypeptide is inhibited.

89. The method of claim 87, wherein said candidate compound is an antisense oligonucleotide.

90-95. -95. (canceled)